BGLF4 is a serine/threonine protein kinase encoded by Epstein-Barr virus. One of the physiological substrates of BGLF4 is viral transactivator BZLF1. In the present study, it was demonstrated that alanine substitution of the serine residue at position 209 (S209A) in BZLF1 eliminated phosphorylation of the protein by BGLF4 in vitro. The S209A mutation in BZLF1, as well as a K102I mutation in BGLF4, which inactivated catalytic activity of the viral kinase, also inhibited formation of a stable BGLF4-BZLF1 complex and downregulation of BZLF1 autotransactivation activity mediated by BGLF4. These results indicate that formation of a stable complex of BGLF4-BZLF1 enables downregulation of BZLF1 autoregulation activity and it appears that BGLF4 phosphorylation of BZLF1 may be involved in these processes.
INTRODUCTION
Epstein-Barr virus (EBV) BGLF4 is a serine/threonine protein kinase and is packaged in the virion tegument, the structural component between the virion nucleocapsid and envelope (Asai et al., 2006; Johannsen et al., 2004; Wang et al., 2005) . BGLF4 is conserved in all members of the family Herpesviridae and is the only protein kinase identified in the EBV genome (Chee et al., 1989; Chen et al., 2000; Kato et al., 2001 Smith & Smith, 1989) . BGLF4 is expressed in the early phase of the lytic infection cycle (Gershburg & Pagano, 2002) and is detected mainly in the nuclei of EBV-infected cells (Gershburg et al., 2004; Wang et al., 2005) . Experiments of BGLF4 knockdown by RNA interference in lytically infected cells have demonstrated that BGLF4 has a role(s) in viral replication, especially in the regulation of expression of a subset of late proteins and nuclear egress of nucleocapsids (Gershburg et al., 2007) . BGLF4 has also been suggested to function in viral DNA replication. Thus, BGLF4 co-localizes with viral DNA replication compartments in the nuclei of EBV-infected cells (Asai et al., 2006; Wang et al., 2005) . BGLF4 also phosphorylates a DNA replication licensing factor, minichromosome maintenance protein 4 (MCM4), at sites whose phosphorylation has been reported to inactivate the DNA helicase activity of the MCM4-MCM6-MCM7 complex (Kudoh et al., 2006) . This MCM4-MCM6-MCM7 inhibitory effect on DNA helicase activity may contribute to blocking host chromosome DNA replication in lytically infected cells. In addition, overexpression of BGLF4 in the absence of other EBV proteins induces premature host chromosome condensation, which might provide more extrachromosomal space to facilitate lytic viral DNA replication (Lee et al., 2007) .
Identification of BGLF4 substrates has suggested additional roles for this protein kinase in EBV infection. So far, in addition to MCM4, as described above, the following have been reported to be substrates for BGLF4: EBV BMRF1, a DNA polymerase processing factor (Chen et al., 2000; Gershburg & Pagano, 2002) ; BGLF4 itself ; EBV nuclear antigen (EBNA)-2, a viral transcriptional regulator of viral and cellular genes (Yue et al., 2005) ; EBNA-LP, a viral transcriptional co-activator of EBNA-2 ; BZLF1, a viral transcriptional regulator involved in the switch from latent to lytic infection (Asai et al., 2006) ; and cellular translation elongation factor 1d . BGLF4 could regulate functions governed by these substrates by phosphorylating the substrates. Among the substrates listed above, BGLF4-mediated phosphorylation of EBNA-LP and EBNA-2 has been shown to affect their transcriptional regulatory activity Yokoyama et al., 2001; Yue et al., 2005) , but the biological significance of BGLF4-mediated phosphorylation of the other substrates remains unclear. Analysis of the BGLF4 phosphorylation site(s) in some of the substrates listed above has also revealed that BGLF4 tends to target the same sites in these substrates as cellular cyclin-dependent kinases (CDKs), suggesting that BGLF4 mimics CDKs Kudoh et al., 2006; Yue et al., 2005) .
We previously demonstrated that BZLF1 is a physiological substrate of BGLF4 in EBV-infected cells (Asai et al., 2006) . Interestingly, the interaction between BGLF4 and BZLF1 in infected cells seems to be stable, based on the observation that BZLF1 co-immunoprecipitated with BGLF4 and that these two viral proteins co-localized in nuclear structures similar to the viral DNA replication compartments in infected cells (Asai et al., 2006) . However, the biological significance of the interaction of BGLF4 with BZLF1 has not been elucidated. Therefore, in the present study, we attempted to map the minimal domain in BZLF1 whose mutation eliminated the BGLF4 phosphorylation of BZLF1 and/or the interaction of BFLF4 with BZLF to investigate the function of the BGLF4-BZLF1 interaction.
METHODS
Cells. The COS-1 and Akata cells used have been described previously (Asai et al., 2006) . HEK293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % fetal calf serum.
Plasmids. Plasmids encoding a series of BZLF1 deletion mutants fused to maltose binding protein (MBP) were constructed by amplifying the BZLF1 domains indicated in Fig. 1(a) by PCR from pcDNA-BZLF1 (Asai et al., 2006) and cloning the DNA fragments into pMAL-c (New England BioLabs). Plasmids encoding MBP-BZLF1-d2-S208A or MBP-BZLF1-d2-S209A in which a serine at BZLF1 codon 208 or 209, respectively, was substituted with an alanine codon were constructed as described previously (Sambrook & Russell, 2001 ). pcDNA3.1-BZLF1 expressing wild-type BZLF1 was constructed by cloning a pcDNA-BZLF1 XbaI-KpnI fragment into pcDNA3.1A(2) (Invitrogen). pcDNA3.1-BZLF1-S209A in which Ser-209 was substituted with alanine was constructed as described previously (Sambrook & Russell, 2001) . pME-BGLF4 expressing wildtype BGLF4 was constructed by amplifying the entire coding sequence of BGLF4 from pAcGHLT-BGLF4 and cloning the DNA fragments into pME18S (Kawaguchi et al., 2000) . pME-BGLF4-K102I was constructed by amplifying the entire coding sequence of BGLF4-K102I, in which the invariant lysine at position 102 was substituted with isoleucine, from pAcGHLT-BGLF4-K102I and cloning the DNA fragments into pME18S. pZp-luc was constructed by amplifying the BZLF1 promoter region (nt 2552 to +2, relative to the BZLF1 transcription initiation site) from EBV DNA isolated from B95-8 cells and cloning the DNA fragments into pGL3-Basic (Promega).
Production and purification of MBP fusion proteins expressed in Escherichia coli. MBP fusion proteins were expressed in E. coli and purified as described previously (Kato et al., 2005 (Kato et al., , 2006 .
Purification of glutathione S-transferase (GST) fusion proteins from baculovirus-infected cells. GST-BGLF4 and GST-BGLF4-K102I proteins were purified from Sf9 cells infected with Bac-GST-BGLF4 and Bac-GST-BGLF4-K102I, respectively, as described previously .
In vitro kinase assays. MBP fusion proteins were captured on amylose beads (New England BioLabs) and used as substrates for in vitro kinase assays with purified GST-BGLF4 and GST-BGLF4-K102I, as described previously .
Antibodies. Rabbit polyclonal antibody to BGLF4 and mouse monoclonal antibody to BZLF1 have been described previously (Asai et al., 2006) . Mouse monoclonal antibody to b-actin (AC15) was purchased from Sigma.
Immunoblotting, immunoprecipitation and luciferase assay.
Immunoblotting, immunoprecipitation and a luciferase assay were On: Mon, 07 Jan 2019 06:43:49 performed as described previously (Kanamori et al., 2004; Kato et al., 2008 Kato et al., , 2009 Kawaguchi et al., 2001) .
EBV lytic cycle induction. EBV-positive Akata cells were treated with 100 mg anti-human IgG ml 21 (Cappel) to induce EBV lytic infection as described previously (Asai et al., 2006) .
Quantitative RT-PCR. For quantitative RT-PCR, total RNA was extracted from Akata cells using a High Pure RNA Isolation kit (Roche) and reverse transcribed to cDNA using a Transcriptor Firststrand cDNA Synthesis kit (Roche). The amount of cDNA was measured using the Universal ProbeLibrary (Roche) with TaqMan Master (Roche) and a LightCycler 1.5 System (Roche) according to the manufacturer's instructions. Gene-specific primers and universal probes were designed by using ProbeFinder software (Roche). The primer and probe sequences for BZLF1 were 59-CCGGCTTGG-TTAGTCTGTTG-39 (forward primer), 59-AGCTTATGCAGCACC-TCAGC-39 (reverse primer) and Universal ProbeLibrary probe # 48 (Roche); and for 18S rRNA were 59-CGATTGGATGGTTTAGTG-AGG-39 (forward primer) and 59-AGTTCGACCGTCTTCTCAGC-39 (reverse primer) and Universal ProbeLibrary probe #81 (Roche). The results were normalized relative to 18S rRNA expression.
RESULTS
Identification of an amino acid in BZLF1 whose mutation eliminates phosphorylation of the protein by BGLF4
We showed previously that, in in vitro kinase assays, purified MBP-BZLF1 protein was specifically phosphorylated by purified BGLF4 fused to GST (GST-BGLF4) (Asai et al., 2006) . To map the minimal domain in BZLF1 whose mutation eliminated phosphorylation of BZLF1 by BGLF4, we constructed a series of MBP-BZLF1 deletion mutants (Fig. 1a) and tested whether these mutants were phosphorylated by GST-BGLF4 in in vitro kinase assays. Using the MBP-BZLF1 deletion mutants as substrates for BGLF4, the phosphorylation site(s) was mapped in the domain encoding BZLF1 codons 208-223 (Fig. 1a, c) . We then mutagenized MBP-BZLF-d2 by replacing the serine at codon 208 with an alanine codon (MBP-BZLF1-d2-S208A) and the serine at codon 209 with an alanine codon (MBP-BZLF1-d2-S209A), and used these mutants as substrates in in vitro BGLF4 kinase assays (Fig. 1b) . As shown in Fig. 1(b, d) , MBP-BZLF1-d2-S208A was efficiently phosphorylated by GST-BGLF4, whereas MBP-BZLF1-d2-S209A was not. These results showed that the S209A mutation in BZLF1 eliminated BGLF4 phosphorylation of the protein in vitro.
Formation of a stable BGLF4-BZLF1 complex
To examine whether BGLF4 phosphorylation of BZLF1 affected the interaction of BGLF4 and BZLF1, COS-1 cells were transfected with plasmids expressing the proteins shown in Fig. 2(a) , solubilized and immunoprecipitated with anti-BGLF4 antibody. The immunoprecipitates were analysed by electrophoresis and immunoblotted with anti-BZLF1 antibody. As reported previously (Asai et al., 2006) , when wild-type BZLF1 and wild-type BGLF4 were coexpressed in COS-1 cells, anti-BGLF4 antibody coprecipitated BZLF1 and BGLF4 (Fig. 2a, left panel, lane  2) . In contrast, when the kinase-inactive BGLF4 mutant BGLF4-K102I was co-expressed with wild-type BZLF1, BZLF1 was not co-precipitated by anti-BGLF4 antibody (Fig. 2a, left panel,  lane 3) . Furthermore, when the mutant BZLF1-S209A, which could not be phosphorylated by BGLF4 in vitro, was co-expressed with wild-type BGLF4, BZLF1-S209A was not co-precipitated by anti-BGLF4 antibody (Fig. 2a, left panel,  lane 5) . The level of expression of BGLF4 and BGLF4-K102I proteins and of BZLF1 and BZLF1-S209A proteins in whole-cell extracts of transfected cells was similar (Fig.  2a, right panels) . Similar results were obtained using HEK293T cells (data not shown). These results indicated that a stable interaction between BGLF4 and BZLF1 was dependent on the catalytic activity of BGLF4 and on the presence of BZLF1 Ser-209, mutation of which eliminated the phosphorylation of BZLF1 by BGLF4 in vitro.
BGLF4 downregulation of BZLF1 transactivation activity of the BZLF1 promoter
It has been reported that BZLF1 regulates EBV gene expression through interaction with various viral promoters including its own (Kieff & Rickinson, 2007) . To investigate the effect of BGLF4 phosphorylation of BZLF1 and the interaction of these two proteins, we tested whether BGLF4 affected the regulatory function of BZLF1 on its own promoter. For these studies, COS-1 cells were co-transfected with the BZLF expression vector(s) indicated in Fig. 2(b) , the reporter gene plasmid pZp-luc containing the BZLF1 promoter upstream of the luciferase reporter gene and pCMV-Rluc (Promega). At 48 h posttransfection, cells were harvested and assayed for firefly and Renilla luciferase activities using a Dual-Glo Luciferase Assay system (Promega). For each reaction, promoter activity was determined from the luciferase activity after normalization for Renilla luciferase activity. The fold activation (Fig. 2b) was the ratio of reporter activity to that of cells transfected with empty expression vectors. As reported previously (Flemington & Speck, 1990) , BZLF1 alone significantly stimulated BZLF1 promoter activity by approximately 20-fold. However, co-expression of BZLF1 and BGLF4 resulted in only a 3-fold increase in BZLF1 promoter activity, indicating that BGLF4 downregulated BZLF1 transactivation activity of its own promoter.
We then examined the effects of mutations in BZLF1 and BGLF4 that inhibited interaction of BGLF4 with BZLF1, such as the S209A mutation in BZLF1 and the K102I mutation in BGLF4, on downregulation of BZLF1 transactivation activity by BGLF4. As shown in Fig. 2(b) , the BZLF1-S209A mutant showed transactivation activity of its own promoter similar to that of wild-type BZLF1, indicating that the S209A mutation had no effect on BZLF1 autoregulation activity. In contrast with wild-type BZLF1, wild-type BGLF4 had little effect on BZLF1-S209A autoregulation activity. Furthermore, repression of BZLF1 autoregulation activity was not observed in the presence of the BGLF4 kinase-inactive mutant (BGLF4-K102I). The levels of BGLF4 and BGLF4-K102I protein expression and of BZLF1 and BZLF1-S209A protein expression in wholecell extracts of transfected cells were similar (Fig. 2c) . Similar results were obtained using HEK293T cells (data not shown). These results indicated that the formation of a stable BGLF4-BZLF1 complex is required for downregulation of BZLF1 transactivation activity of its own promoter.
Expression of BGLF4 protein and BZLF1 mRNA in EBV-infected cells
The observation that BGLF4 repressed BZLF1 autoregulation activity suggested that BGLF4 might modulate BZLF1 mRNA expression in EBV-infected cells. To pursue this possibility, we investigated the correlation between the expression of BGLF4 protein and BZLF1 mRNA in EBVinfected cells. For these studies, EBV-positive Akata cells were treated with anti-human IgG to induce EBV lytic infection and were harvested at the indicated times (Fig. 3) . Each sample was then assayed to quantify BZLF1 mRNA by quantitative RT-PCR and to detect BGLF4 proteins by immunoblotting. As shown in Fig. 3(b) , the level of BZLF1 mRNA increased after 1.5 h, peaked at 3-6 h and then decreased continuously from 9 to 21 h. These results were consistent with a previous report (Yuan et al., 2006) . BGLF4 proteins became detectable at 9 h, when the level of BZLF1 mRNA began to decrease, and the level of BGLF4 protein remained relatively constant thereafter (Fig. 3a) . Thus, the amount of BZLF1 mRNA in EBV-infected cells decreased as BGLF4 began to be expressed at a detectable level. 
DISCUSSION
In the present study, we have demonstrated that inhibition of a stable BGLF4-BZLF1 complex by an S209A mutation in BZLF1 or K102I mutation in BGLF4 eliminated downregulation of BZLF1 autoregulation activity mediated by BGLF4. Therefore, we concluded that the interaction between BGLF4 and BZLF1 is critical for downregulation of BZLF1 autoregulation activity. Similarly, it has been reported that a Kaposi's sarcoma-associated herpesvirus (KSHV) homologue of EBV BGLF4 is involved in the regulation of transcriptional regulatory activity of a KSHV homologue of EBV BZLF1 (Izumiya et al., 2007) .
We and other groups previously demonstrated that BGFL4 targets the same sites in its substrates as CDKs Kudoh et al., 2006; Yue et al., 2005) . Based on the observation that an amino acid substitution in BZLF1 of Ser-209 with alanine abolished the phosphorylation of BZLF1 by BGLF4 in vitro, it seems highly probable that Ser-209 is a BGLF4 phosphorylation site in BZLF1. In contrast with the previous reports, bioinformatic analyses revealed that BZLF1 does not contain putative CDK sites (data not shown) and that the flanking sequence of BZLF1 Ser-209 (SSEND) matches the consensus phosphorylation site for casein kinase II (CKII) (X-S/T-X-X-E/D). These observations suggest that targets of BGLF4 are not restricted to CDK sites and that BGLF4 has broader targets than previously expected. Consistent with this, varicellazoster virus BGLF4 homologue ORF47 recognizes a consensus sequence similar to that of CKII (Kenyon et al., 2002) . To determine the molecular mechanism(s) by which a protein kinase acts on its substrate requires demonstration that the altered phenotype(s) of a protein kinase mutant with attenuated or no catalytic activity is also found with the substrate mutant in which the phosphorylation site(s) has been modified by a mutation(s). In the present study, we presented data that the mutation in the putative BGLF4 phosphorylation site Ser-209 in BZLF1, as well as the BGLF4 K102I mutation inactivating catalytic activity of the viral kinase, eliminated formation of a stable BGLF4-BZLF1 complex and downregulation of BZLF1 autoregulation activity mediated by BGLF4. Therefore, it could be hypothesized that BGLF4 phosphorylation of BZLF1 enabled the formation of a stable BGLF4-BZLF1 complex, which downregulated BZLF1 autoregulation activity. We should note, however, that there is a possibility that the replacement of Ser-209 with alanine by chance causes a conformational change in BZLF1 and that the defect in phosphorylation of the mutated BZLF1 by BGLF4 in vitro was due to steric hindrance of the target protein caused by the mutation. Furthermore, it is also possible that the phenotypes observed with the BZLF1-S209A mutant are also due to steric hindrance of BZLF1 caused by the amino acid replacement, rather than prevention of phosphorylation on Ser-209 of BZLF1.
The first gene products expressed during herpesvirus replication are the immediate-early (IE) gene products, which have multiple roles in modifying the host cellular environment to facilitate viral replication (Mocarski et al., 2007; Roizman et al., 2007) . These roles include regulation of transcription, translation, the cell cycle, protein degradation, mRNA transport, apoptosis, interferon activation and antigen presentation (Mocarski et al., 2007; Roizman et al., 2007) . As herpesvirus IE gene products have dramatic effects on host cells, as described above, IE gene expression must be tightly regulated during viral replication. It has been well documented that multiple mechanisms for regulation of IE gene expression have been conserved during the evolution of alpha-and betaherpesviruses, such as herpes simplex virus and human cytomegalovirus. These viruses have both positive and negative mechanisms for regulating IE gene expression (Mocarski et al., 2007; Roizman et al., 2007) , which lead to appropriate IE gene expression at specific stages of viral replication. Similarly, the mechanisms by which an EBV IE gene, BZLF1, is activated by BZLF1 itself and/or cellular transcription factors have been documented. It has been reported that activation of BZLF1 gene expression during EBV reactivation involves initial activation by cellular factors followed by an autoactivation step (Flemington & Speck, 1990; Yin et al., 2004) . However, mechanisms for downregulation of BZLF1 gene expression have not been reported, although it has been reported that the level of BZLF1 mRNA peaks and then decreases in cells lytically infected with EBV (Yuan et al., 2006) .
In the present study, we showed that BGLF4 downregulated BZLF1 transactivation activity of its own promoter in luciferase reporter gene assays. As BZLF1 autoregulation activity has been considered to be critical for activation of BZLF1 gene expression (Flemington & Speck, 1990; Yin et al., 2004) , suppression of BZLF1 autoregulation activity may result in downregulation of BZLF1 gene expression. Therefore, there is a possibility that BGLF4 is one of the factors that play a role in regulation of BZLF1 gene expression in EBV-infected cells by attenuating BZLF1 transactivation activity. Consistent with this, we demonstrated that, in lytically infected Akata cells, the level of BZLF1 mRNA peaked at 6 h and decreased thereafter, with the decrease in BZLF1 mRNA being correlated with BGLF4 protein expression. These observations also imply that EBV has evolved a mechanism for downregulating IE gene expression similar to other alpha-and betaherpesviruses. However, the direct involvement of BGLF4 in downregulation of BZLF1 mRNA expression in EBVinfected cells remains to be elucidated. Further studies using EBV recombinants lacking BGLF4 will be needed to address this issue and are in progress in our laboratory. 
